Incyte, Lilly get FDA OK for rheumatoid arthritis drug – but with conditions

The approval, which includes a box warning requirement, triggered a $100M payment from Lilly to Incyte.

Source: bizjournals.com Health Care:Biotechnology headlines - June 4, 2018 Category: Biotechnology Authors: John George Source Type: news